Key result
Higher visit-to-visit LDL-C variability is linked to ~16% more coronary events per SD in CAD.
Why the study?
Does visit-to-visit LDL-C variability predict cardiovascular outcomes in patients with coronary artery disease?
RCT (n=9,572)
randomly assigned
Does visit-to-visit LDL-C variability predict cardiovascular outcomes in patients with coronary artery disease?
Answers are grounded in this paper and cite their sources.
Visit-to-visit LDL-C variability is an independent predictor of cardiovascular events in patients with coronary artery disease, regardless of the achieved LDL-C level.
BACKGROUND: Studies demonstrate that lowering low-density lipoprotein cholesterol (LDL-C) using a statin is associated with significant reduction in cardiovascular events. Whether visit-to-visit variability in LDL-C levels affects cardiovascular outcomes is unknown. OBJECTIVES: This study sought to evaluate the role of visit-to-visit variability in LDL-C levels on cardiovascular outcomes. METHODS: We evaluated patients with coronary artery disease and LDL-C <130 mg/dl enrolled in the TNT (Treating to New Targets) trial, randomly assigned to receive atorvastatin 80 mg/day versus 10 mg/day and with at least one post-baseline measurement of LDL-C. Visit-to-visit LDL-C variability was evaluated from 3 months into random assignment through the use of various measurements of LDL-C variability: SD, average successive variability (ASV), coefficient of variation, and variation independent of mean, with the first 2 measurements used as the primary measurements. Primary outcome was any coronary event, and secondary outcomes were any cardiovascular event, death, myocardial infarction, or stroke. RESULTS: Among 9,572 patients, SD and ASV were significantly lower with atorvastatin 80 mg/day versus 10 mg/day (SD: 12.03 ± 9.70 vs. 12.52 ± 7.43; p = 0.005; ASV: 12.84 ± 10.48 vs. 13.76 ± 8.69; p < 0.0001). In the adjusted model, each 1-SD increase in LDL-C variability (by ASV) increased the risk of any coronary event by 16% (hazard ratio [HR]: 1.16; 95% confidence interval [CI]: 1.10 to 1.23; p < 0.0001), any cardiovascular event by 11% (HR: 1.11; 95% CI: 1.07 to 1.15; p < 0.0001), death by 23% (HR: 1.23; 95% CI: 1.14 to 1.34; p < 0.0001), myocardial infarction by 10% (HR: 1.10; 95% CI: 1.02 to 1.19; p = 0.02), and stroke by 17% (HR: 1.17; 95% CI: 1.04 to 1.31; p = 0.01), independent of treatment effect and achieved LDL-C levels. Results were largely consistent when adjusted for medication adherence. CONCLUSIONS: In subjects with coronary artery disease, visit-to-visit LDL-C variability is an independent predictor of cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Bangalore et al. (2015) conducted an RCT in coronary artery disease and LDL-C <130 mg/dl (n=9,572). Visit-to-visit LDL-C variability was evaluated on any coronary event (HR 1.16, 95% CI 1.10 to 1.23, p=< 0.0001). Each 1-SD increase in visit-to-visit LDL-C variability increased the risk of any coronary event by 16% in patients with coronary artery disease.
Synapse has enriched 10 related papers. Consider them for comparative context: